Prevention of mother-to-child transmission and elimination of mother-to-child transmission — the integrated programmatic framework combining antiretroviral therapy during pregnancy and breastfeeding, safe delivery practices, infant prophylaxis, and community engagement — has reduced vertical HIV transmission from twenty-five to thirty percent to less than two percent in high-performing programs, with the PMTCT EMTCT Market reflecting the pharmaceutical, diagnostic, and health systems investments required to achieve the global goal of less than five percent transmission by 2030.

Option B+ and universal treatment — the WHO 2013 shift from CD4-based antiretroviral eligibility to immediate lifelong ART for all pregnant and breastfeeding women (Option B+), transforming PMTCT from short-term prophylaxis to chronic disease management. The dolutegravir-based regimens (DTG/3TC/TDF) now recommended as preferred first-line for pregnant women based on Tsepamo study safety data, with single-pill fixed-dose combinations improving adherence and reducing pharmacy complexity in resource-limited settings where PMTCT programs operate.

Point-of-care viral load and early infant diagnosis — the transition from dried blood spot PCR sent to centralized laboratories (turnaround 4-8 weeks) to point-of-care nucleic acid testing (Cepheid GeneXpert, Abbott m-PIMA) providing same-day results for infant HIV diagnosis at 4-6 weeks and maternal viral load monitoring. The test-and-treat paradigm requiring rapid turnaround to inform clinical decisions on infant prophylaxis duration and maternal regimen adherence support, with POC EID demonstrating increased result return rates and faster ART initiation compared to conventional laboratory networks.

Breastfeeding and prolonged infant prophylaxis — the recognition that in resource-limited settings, breastfeeding with maternal ART and infant nevirapine prophylaxis (through 12 months in high-risk scenarios) provides lower overall HIV-free survival risk than formula feeding with its associated infectious and nutritional morbidity. The PROMISE trial and subsequent programmatic data supporting extended infant prophylaxis for high-risk breastfed infants (maternal viral load detectable, late maternal ART initiation, incident infection during breastfeeding).

Do you think the EMTCT goal of less than two percent transmission is achievable globally, or will persistent health systems gaps in sub-Saharan Africa maintain residual transmission above target levels?

What does PMTCT and EMTCT stand for, and what is the difference? PMTCT: Prevention of Mother-to-Child Transmission — the comprehensive package of interventions to reduce HIV transmission from HIV-positive mother to child during pregnancy, labor, delivery, and breastfeeding. Core interventions: Maternal ART (antiretroviral therapy); safe obstetric practices (avoid unnecessary invasive procedures); infant ARV prophylaxis; safe infant feeding counseling; family planning integration. EMTCT: Elimination of Mother-to-Child Transmission — the programmatic goal defined by WHO as achieving less than fifty new pediatric infections per 100,000 live births and less than five percent transmission rate (breastfeeding populations) or less than two percent (non-breastfeeding populations); requires validated certification process (silver, gold, platinum tiers based on data quality and service coverage). Difference: PMTCT is the intervention package; EMTCT is the validated outcome status and certification framework.

What is the current recommended antiretroviral regimen for pregnant women? Preferred first-line: Dolutegravir (DTG) 50 mg + lamivudine (3TC) 300 mg + tenofovir disoproxil fumarate (TDF) 300 mg — single tablet once daily (Tivicay + generic NRTI backbone, or fixed-dose combination where available). DTG advantages: High barrier to resistance; rapid viral suppression; favorable safety profile in pregnancy (Tsepamo study — no increased neural tube defect risk with periconception exposure in updated data; initial signal resolved with larger dataset). Alternative: Efavirenz (EFV)-based regimen if DTG contraindicated or not available; EFV remains safe and effective in pregnancy despite earlier neuropsychiatric concerns. For women already on ART: Continue current regimen if virally suppressed; switch to DTG if on failing or suboptimal regimen; avoid EFV if experiencing CNS side effects. Special situations: PI-based regimen (lopinavir/ritonavir) if protease inhibitor resistance; integrase strand transfer inhibitor alternatives (raltegravir, bictegravir — limited pregnancy data but generally considered safe).

What are the remaining barriers to achieving EMTCT in high-burden countries? Health systems: Stock-outs of ARV drugs and reagents; limited healthcare worker density (sub-Saharan Africa averages 0.2-0.5 doctors per 1,000 population vs. 2.5+ in high-income countries); weak supply chain and cold chain; laboratory infrastructure gaps (viral load testing coverage often <50%). Patient-level: Late antenatal care presentation (many women first contact health system in third trimester); poor ART adherence (structural barriers — transportation, food insecurity, stigma); loss to follow-up postpartum (transition from maternal health to ART clinic often fragmented); disclosure challenges and intimate partner violence. Community: HIV stigma and discrimination; traditional birth attendant practices bypassing facility delivery; breastfeeding norms conflicting with safe feeding counseling; gender inequality limiting women's healthcare decision-making. Programmatic: Insufficient integration of PMTCT with family planning, cervical cancer screening, and adolescent health services; limited male partner involvement; inadequate data systems for tracking mother-infant pairs. Financial: Donor dependency (PEPFAR, Global Fund); domestic health spending often <5% GDP in high-burden countries; out-of-pocket costs despite free care policies (informal payments, transportation).

#PMTCT #EMTCT #HIVPrevention #MotherToChildTransmission #AntiretroviralTherapy #GlobalHealth